Drug use-results survey on safety and efficacy of Rupafin tablets 10 mg

Drug use-results survey on safety and efficacy of Rupafin tablets 10 mg - Drug use-results survey on safety and efficacy of Rupafin tablets 10 mg

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031332

Enrollment

2500

Registered

2018-02-16

Start date

2018-01-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis Hives and itch associated with skin diseases ( eczema / dermatitis, cutaneous pruritus)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients newly treated by RUPAFIN

Exclusion criteria

Exclusion criteria: Patients with a history of hypersensitivity to the active substance or to any of the excipients.

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness(Assessment by physician)	—

Secondary

Measure	Time frame
Effectiveness(Condition of symptoms for each indication during the medication)	—

Countries

Japan

Contacts

Public ContactYasushi Horikawa, Kazuhito Okada

TEIKOKU SEIYAKU CO.,LTD. Safety Management Unit

gpsp@teiyaku.co.jp0879-25-2435

Outcome results